Maravai Lifesciences Holdings Inc (MRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Maravai Lifesciences Holdings Inc (MRVI) Stock Forecast
Analysts expect Maravai Lifesciences Holdings (MRVI) to earn -$0.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $214.30M. Of 9 analysts, 5 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.44, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 56% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 55.6% |
| Hold | 4 | 44.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 4.8%.
- Fiscal year ending Dec 31, 2026
- -$0.07
- EPS consensus, revenue $214.30M
- Fiscal year ending Dec 31, 2027
- -$0.08
- EPS consensus, revenue $224.56M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.09 to -$0.05 | 8 | $214.30M | $212.50M to $215.20M | 9 |
| Dec 31, 2027 | -$0.08 | -$0.17 to $0.00 | 9 | $224.56M | $215.30M to $232.50M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.04 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.04 | -$0.06 to -$0.02 | 11 | $52.20M | $48.41M to $54.70M | 11 |
| Mar 31, 2027 | -$0.01 | -$0.04 to $0.01 | 4 | $61.09M | $54.20M to $70.00M | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 6 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.07 | -$0.11 | -$0.11 | -$0.18 | -$0.18 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.08 | -$0.10 | -$0.10 | -$0.11 | -$0.10 | N/A |
| Quarter ending Mar 31, 2027 | -$0.01 | $0.00 | $0.00 | $0.00 | $0.00 | N/A |
Frequently Asked Questions About MRVI
What is the MRVI stock forecast?
Consensus analyst estimates put Maravai Lifesciences Holdings's EPS at -$0.07 for the fiscal year ending Dec 31, 2026, on revenue of $214.30M. The consensus rating from 9 analysts is Buy.
How do analysts rate MRVI stock?
Of 9 analysts covering Maravai Lifesciences Holdings, 0 rate it Strong Buy, 5 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MRVI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.07, with estimates from -$0.09 to -$0.05 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.17 to $0.00 from 9 analysts.
What revenue do analysts expect from Maravai Lifesciences Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $214.30M, with estimates from $212.50M to $215.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $224.56M, with estimates from $215.30M to $232.50M.
How many analysts cover MRVI?
9 analysts rate Maravai Lifesciences Holdings stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MRVI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors